Compare Harley-Davidson Inc (HOG) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harley-Davidson Inc vs Organon & Co. Common Stock — how do they compare? Harley-Davidson Inc trades at $26.92 (market cap $2.86B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Organon & Co. Common Stock is the larger of the two by market cap, and Harley-Davidson Inc pays the higher dividend (2.73%). Which is the better fit depends on your goals — on Pluang, investors hold Harley-Davidson Inc for 92 Days and Organon & Co. Common Stock for 0 Days on average.
| HOG | OGN | |
|---|---|---|
Market Cap | $2.86B | $3.62B |
Volume | 1,391,703 | 2,892,999 |
Sector | Consumer Cyclical | Health |
52-Week High | $28.46 | $13.81 |
52-Week Low | $17.19 | $5.70 |
Typical Hold Time | 92 Days | 0 Days |
Enterprise Value | $3.27B | $11.04B |
Dividend Yield | 2.73% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Harley-Davidson (HOG) trades at $26.96, down 1.5% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a Q2 2026 EPS beat ($0.75 actual vs. $0.645 expected) but missed in Q4 2025 and Q1 2026. Revenue has declined from $5.8B in 2022 to $4.5B in 2025, with net income margin falling to 4.78%. Recent news highlights tariff risks and a data breach investigation, while analyst consensus is a $28.50 price target with a Hold-heavy rating.
The outlook is cautious; HOG faces revenue pressure and margin compression, offset by low valuation multiples (P/E 15.26, P/S 0.74) and a dividend. Key risks include competitive threats, tariff exposure, and economic sensitivity. Upside depends on execution of the 'Back to the Bricks' plan stabilizing sales, but investor sentiment remains neutral amid institutional selling and mixed earnings trends.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
